Gene expression of Epithelial Membrane Protein 2 gene and β1-Integrin gene in patients with breast cancer

Samah EL-Ghlban,∗ Elsayed Saber AbouElnour,∗∗ Abd El-Monem Abd El- Kader EL- Torgoman, Saeed Mohamed Saeed Abu Elabas

Biochemistry Division Department of Chemistry, Faculty of Science, El Menoufia University, Shebin El-Kom, Egypt

Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Egypt

Department of Chemistry, Faculty of Science, El Menoufia University, Shebin El-Kom, Egypt

ARTICLE INFO

Keywords:
Breast cancer
EMP2
β1-integrin and CA 15–3

ABSTRACT

Background: Breast cancer is the most common invasive cancer and the leading cause of cancer death in women. The function of over a thousand genes is reported as affected by genetic modifications in breast cancer.

Objectives: To study the gene expression of Epithelial Membrane 2 (EMP2) and β1-Integrin genes in patients with breast cancer.

Subjects and methods: This study was carried out by cooperation between the Biochemistry Division Department of Chemistry, Faculty of Science and Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University. This study included 120 subjects divided into 2 groups Group I: Included 60 women with breast cancer undergoing modified radical mastectomy. Tissue specimens were taken from the cancerous breast tissue and from the marginal healthy breast tissues. Group II: Included 60 age and sex-matched apparently healthy women served as a control group. All patients participants were subjected to full history taking, general clinical examination, abdominal ultrasound, CT-scan for abdomen, mammography, fine needle biopsy, histopathological examination, immunostaining of tissues, metastatic work up (chest x-ray and bone scan) and laboratory investigations including: Complete blood count (patients and controls), serum carbohydrate antigen 15–3 (patients and controls), detection of EMP2 and β1-Integrin genes expression in the tissue samples by formation of cDNA by reverse transcription PCR after RNA extraction and real-time PCR using SYBR Green technique.

Results: Compared to healthy tissues, the breast cancer tissues had significant higher EMP2 and β1-Integrin gene expression levels. Also, there was a significant increase in CA15-3 in patients group as compared with the control group. It was found that EMP2 and β1-Integrin expression in malignant tissue samples correlates with advanced and metastatic disease.

Conclusion: The gene expression of EMP2 and β1-Integrin are important markers for the severity of breast cancer and they are good indicators of its prognosis.

1. Introduction

Breast cancer is the most common invasive cancer and the leading cause of cancer death in women. It is the result of dysregulation of gene networks that maintain normal cellular functions and identity [1].

Breast cancer originates from the transformation of breast epithelial cells found either lining the milk ducts or in the milk-producing lobules of the breast. Lobules and ducts are formed from three lineages of cells in two layers: the myoepithelial layer is common to both structures and forms the basal layer, while ductal epithelial cells line the ducts and alveolar epithelial cells synthesize the milk within the lobules [2,3].

Epithelial membrane protein-2 (EMP2) is a member of the growth arrest-specific gene 3/peripheral myelin protein-22 (GAS3/PMP22) subfamily, which together with tetraspanins and connexins comprise three subfamilies of the large 4-transmembrane family EMP2 was identified as a novel prognostic indicator in a number of gynecological cancers [4]. Its expression is increased in the breast, ovarian and endometrial cancers in which it has been shown to correlate with poor survival and/or advanced disease [5]. Practically, the best-known tetraspan proteins are connexins, which form the major structural element...
of gap junctions. Connexins play vital parts in the regulation of cell growth and differentiation. Cancer cells generally have down-regulated levels of gap junctions. Moreover, numerous lines of evidence suggest that loss of gap junctional intercellular communication is an important step in carcinogenesis. Re-expression of connexins in cancer cells causes normalization of cell growth control and reduced tumor growth [6].

Integrins, which are transmembrane receptors in a large family of 18 α and 8 β heterodimeric transmembrane proteins, were well known as adhesion molecules in mediating cell-Extracellular matrix (ECM) interaction [7]. Integrins are important sensors of the cell microenvironment and regulate many intracellular and extracellular signaling pathways involving the organization of cells, tissues and organs during development in response to structural variations of the ECM. Integrins have been implicated in many processes associated with tumor cell adhesion to the ECM, including migration, invasion, and metastasis [8–10]. Integrins also plays significant roles in regulating cell apoptosis-associated gene expression [11].

β1-Integrin is highly expressed in most tumors and is associated with a negative prognostic significance such as overall and disease-free survival, recurrence, and metastasis for head and neck and squamous cell carcinoma, melanoma, lung, breast, prostate, laryngeal and pancreatic cancers [12].

The aim of this work was to study the gene expression of Epithelial Membrane Protein 2 and β1-Integrin genes in patients with breast cancer.

2. Patients and methods

2.1. Patients

This study was carried out by cooperation between the Biochemistry

Table 1

|                      | Patients Group I (N = 60) | Control Group II (N = 60) | Test of sig. | P     |
|----------------------|--------------------------|--------------------------|--------------|-------|
| No.                  | %                        | No.                      | %            |       |
| Age (years) ≤50      | 36                       | 60.0                     | 38           | 63.0  | χ² = 0.205 | 0.651 |
| > 50                 | 24                       | 40.0                     | 22           | 37.0  |           |      |
| Age (years) Mean ± SD.| 50.6 ± 11.8              | 49.9 ± 10.8              | t = 0.340    | 0.735 |
| RBCs ( × 10⁹/µl)     | 4.13 ± 0.3               | 4.38 ± 0.49              | t = 3.565    | 0.001* |
| Hb (g/dl)            | 11.41 ± 0.92             | 12.16 ± 1.02             | 4.291*       | < 0.001* |
| HCT (%)              | 34.85 ± 2.74             | 36.1 ± 2.86              | 2.436        | 0.016* |
| MCV (fl)             | 83.12 ± 5.13             | 82.7 ± 4.32              | 0.492        | 0.642 |
| MCHC (g/dl)          | 31.04 ± 6.04             | 31.35 ± 6.14             | 0.273        | 0.786 |
| MCHC (g/dl)          | 6.39 ± 1.74              | 33.7 ± 1.0               | 4.498*       | < 0.001* |
| Platelets ( × 10⁹/µl)| 231.33 ± 41.64           | 227.92 ± 37.9            | 0.470        | 0.639 |
| CA 15–3[II/mL]       | 35.29 ± 6.1              | 12.29 ± 7.46             | U = 50.0*    | < 0.001* |

χ², p: χ² and p values for Chi square test for comparing between the two groups.

Table 2

| genes                | healthy tissue (no 60) Mean ± SD. | malignant tissue (no 60) Mean ± SD. | Z     | P     |
|----------------------|-----------------------------------|-------------------------------------|-------|-------|
| RQ of EMP2           | 0.67 ± 1.36                       | 8.59 ± 6.9                         | 8.801 | < 0.001* |
| RQ of β1-Integrin    | 0.81 ± 0.59                       | 15.14 ± 12.34                      | 9.45  | < 0.001* |

Z, p: Z and p values for Wilcoxon signed ranks test for comparing between normal and cancer.

Table 3

| Tumor Size | Grade | Stage | Carcinoma in situ | Multicentric |
|------------|-------|-------|-------------------|--------------|
| Age (years) | r = -0.211 | -0.334 | -0.173 | -0.096 | -0.147 |
| P          | 0.263 | 0.071 | 0.360 | 0.615 | 0.439 |
| Affected lymph node | r = 0.302 | -0.083 | 0.236 | -0.033 | -0.042 |
| Molecular type | r = 0.105 | 0.664 | 0.209 | 0.861 | 0.824 |
| Molecular type | r = 0.209 | 0.010* | 1.000 | 0.472 | 1.000 |
| Hb (g/dl) | r = -0.262 | 0.169 | -0.436* | -0.035 | 0.440* |
| WBCs ( × 10⁹/µl) | r = 0.163 | 0.372 | 0.016* | 0.854 | 0.015* |
| Platelets ( × 10³/µl) | r = 0.193 | 0.002* | 0.000* | 0.000 | 0.000 |
| CA 15–3 (II/mL) | r = 0.061 | 0.084 | 0.018 | 0.104 | -0.042 |

r: Pearson coefficient, *: Statistically significant at p ≤ 0.05.
Division Department of Chemistry, Faculty of Science and Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University. It included 120 subjects divided into 2 groups

**Group I**: Included 60 women with breast cancer undergoing modified radical mastectomy selected from the General Surgery Department, Menoufia University Hospital in the period from February to June 2017. Tissue specimens were taken from the cancerous breast tissue and from the marginal healthy breast tissues. **Group II**: Included 60 age and sex-matched apparently healthy women served as a control group.

### 2.2. Criteria of selection of patients

Proved breast cancer by mammography, ultrasound, breast MRI and fine Needle Aspiration cytology.

### 2.3. Exclusion criteria

Patients with preoperative chemo or radiotherapy. Patients diagnosed with previous breast tumors or with tumors located elsewhere. Informed written consent was obtained from all subjects who participated in this study. The protocol was approved by the Ethical Committee of Medical Research, Faculty of Science, Menoufia University.

### 2.4. All studied patients were subjected to the following

Full history taking: Including the family history of breast cancer, degree of relationship to a family member (first or greater), multiple cases in the family (particularly on one side): Age at the onset of breast cancer, bilateral disease, other related early-onset tumors (e.g. ovary, sarcoma). General clinical examination, abdominal ultrasound and CT-scan for the abdomen, mammography, fine needle biopsy and histopathological examination, metastatic workup: chest x-ray and bone scan. Laboratory investigations including: Complete Blood Count (CBC) (patients and controls), serum carbohydrate antigen 15-3 (CA15-3) level by enzyme-linked immunosorbent assay (ELISA) (patients and controls), pathological examination of tissue for grading, staging and detection of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu) and detection of EMP2 and β1-Integrin genes expression in cDNA samples prepared from RNA extracted from the malignant and the marginal benign tissue samples using real-time PCR using SYBR Green technique.

Complete blood count (CBC) was done Sysmex XN-1000 Automated Hematology Analyzer (Sysmex Corporation, Kobe 651–0073, Japan). CA15-3 level was determined by ELISA, using. Human CA15-3 ELISA kit purchased from Monobind Company, China [13].

Two fresh parts of the excised mass were collected in 2 Eppendorf tubes one for malignant tissues and the other for adjacent healthy tissue and kept in – 80 for further RNA extraction and an assay of EMP2 and β1-Integrin genes expression.

RNA Isolation from the tissue by (Direct –zol RNA Miniprep) kit Zymo Research.

Two-step RT–PCR was done as follows:

**First Step - PCR: cDNA Synthesis (RT- Step):** (Quant iTect Reverse Transcription Kit, Qiagen, Applied Biosystems, USA, 2012).

For reverse transcription step, samples were prepared in a final volume of 20 µl containing RT buffer, Multi scribe reverse transcriptase (PE Applied Biosystems), and 20 ng total RNA. Then the samples were incubated at 25 °C for 10 min and at 48 °C for 30 min. Heating to 95 °C for 5 min inactivated the reverse transcriptase on 2720 thermal cycler.

Second Step- PCR: cDNA Amplification with SYBR Green II with low ROX for detection of EMP2 and β1-Integrin genes expression: (Quant iTect SYBR Green PCR Kit, Applied Biosystems, USA).

Forward primers and reverse primers were used with SensiFAST™ SYBR® Lo-ROX Kit, nuclease-free water, cDNA in a total reaction volume 25 µl and using GAPDH as endogenous control using the 7500 Real-time PCR system (Applied Biosystems, Foster City, CA, USA).

Forward and reverse primers of EMP2 were (5’-TCTCTCACCACCAT TCTCT-3’) and (5’-AAAACCTCTCTCCTGCTTCA-3’) respectively [14].

Forward and reverse primers of β1-Integrin were (5’- TCACACCC TTGTGACAC-3’) and (5’-GAGATCTGCATCTCAGGGA-3’) respectively [12].

Forward and reverse primers of GAPDH (endogenous control) were (5’-CAGCTCTCCACCATTTTGAC-3’) and (5’-ACCCGTGTGTCTGTA GCA-3’) respectively [15].

Each primer was reconstituted by the addition of the labeled amount of TE buffer after centrifugation, the contents of the vial were mixed by vortexing. 2x QuantiTect SYBR Green PCR Master Mix, cDNA, primers, and RNase-free water were thawed and the individual solutions were mixed. The reaction mix was prepared for each primer in a separate well each with a total reaction volume of 25 µl.

Data analysis using Applied Biosystems 7500, version software 2.0.1. Using the comparative CT method.

Slices from the tumor mass were then immersed in formalin and were submitted to routine tissue processing ending with paraffin-embedded blocks formation. Tumors were graded according to the criteria of Nottingham modification in the Bloom-Richardson system [16]. Tumor staging was performed according to Tumor Node Metastasis (TNM) staging system [17].

### 2.5. Immunohistochemical (IHC) Staining

The method used for immunostaining was a streptavidin-biotin–n–amplified system. From each block, 4 µm thick sections were cut on positively charged slides, which were subjected to subsequent steps of deparaffinization, rehydration and antigen retrieval by boiling in citrate buffer saline (pH 6) followed by cooling at room temperature. The primary antibodies were incubated overnight at room temperature and they included ER (clone 1D5; Dilution, 1:50). (DakoCytomation), PR (clone IA6; Dilution, 1:50) (DakoCytomation) and HER2/neu (clone 250, Dilution, 1:100) (DakoCytomation). Breast cancer cases positive for ER, PR and HER2/neu were used as positive control slides. Negative control slides were also included in each run and prepared by the replacement of primary antibodies by the buffer solution. The secondary antibody was applied with diaminobenzidine as a chromogen substrate and Mayer’s hematoxylin as a counterstain.

**2.6. Immunostaining Interpretation**

ER and PR were considered positive if ≥ 1% of tumor cell nuclei are immunoreactive [18]. HER2/neu immunoreactivity was evaluated...
according to the American Society of Clinical Oncology guideline recommendations [19]. Positive HER2/neu cases were defined as 3 positivity (>10% intense and complete staining); however, score 0 or 1 was considered negative.

According to the IHC results of ER, PR and HER2/neu, the cases were classified into:

- Luminal subtype: positive ER and/or PR and negative HER2/neu.
- HER2/neu positive subtype: negative ER, negative PR and positive HER2/neu.
- Triple-negative subtype: negative ER, negative PR and negative HER2/neu [20].

2.7. Statistical analysis

Results were collected, tabulated, statistically analyzed by IBM’s personal computer and statistical package SPSS version 20. Two types of statistics were done. Chi-square test ($x^2$) is a test of significance used to study the association between two qualitative variables. Odd ratio, describes the probability that people who are exposed to a certain factor will have a disease compared between the two groups. Mann-Whitney test for abnormally distributed quantitative variables comparing between two groups.

Kruskal-Wallis test for abnormally distributed quantitative variables, to compare between more than two studied groups, P-value $<$ 0.05 was considered statistically significant.

3. Results

There was no significant statistical difference in the age of patients group as compared with the control group. There was significant decrease in RBCs, Hb, HCT and MCHC in patients group as compared with the control group. While the non-significant decrease in MCH and non-significant increase in MCV, WBCs and platelets count. A significant increase in CA15-3 in patients group as compared with the control group (Table 1).

Regarding the EMP2 gene and β1-Integrin gene expression, there was a significant statistical increase of EMP2 gene and β1-Integrin gene expression in malignant tissues compared to healthy tissues (Table 2).

There was a significant positive correlation between grade and the molecular type and between multicentric and Hb, while there was a significant negative correlation between grade and Hb, between

$\cdots$

Table 4

| Correlation between different parameters for patients group (n = 60). |
|---------------------------------------------------------------|
| **ER** | **PR** | **HER2/neu** | **EMP2 Normal** | **EMP2 Malignant** | **β1- integrin Normal** | **β1- integrin Malignant** |
|------|-------|-------------|-----------------|-------------------|------------------------|------------------------|
| Age (years) r | 0.211 | 0.211 | -0.246 | 0.285 | -0.276 | 0.012 | -0.252 |
| P | 0.264 | 0.264 | 0.190 | 0.126 | 0.140 | 0.951 | 0.178 |
| Affected lymph node r | 0.350 | 0.350 | -0.205 | 0.178 | -0.225 | 0.171 | -0.028 |
| P | 0.058 | 0.058 | 0.278 | 0.347 | 0.231 | 0.366 | 0.882 |
| Molecular type r | -0.914* | -0.914* | 0.241 | -0.397* | 0.689* | -0.275 | 0.430* |
| P | < 0.001* | < 0.001* | 0.200 | 0.030* | < 0.001* | 0.142 | 0.018* |
| Hb (g/dl) r | 0.154 | 0.154 | 0.198 | -0.289 | -0.144 | 0.072 | -0.009 |
| P | 0.415 | 0.415 | 0.295 | 0.122 | 0.449 | 0.704 | 0.963 |
| WBCs ($\times 10^3/\mu l$) r | 0.153 | 0.153 | -0.072 | 0.264 | -0.024 | 0.256 | -0.006 |
| P | 0.419 | 0.419 | 0.706 | 0.158 | 0.899 | 0.172 | 0.973 |
| Platelets ($\times 10^3/\mu l$) r | -0.222 | -0.222 | -0.075 | -0.079 | 0.269 | 0.066 | 0.180 |
| CA 15–3 (IU/ml) r | -0.009 | -0.009 | -0.071 | 0.150 | -0.197 | 0.050 | 0.037 |
| P | 0.964 | 0.964 | 0.708 | 0.430 | 0.297 | 0.792 | 0.844 |

r: Pearson coefficient, *: Statistically significant at p ≤ 0.05.

Table 5

| Univariate and multivariate analysis for the parameters affecting grade in patients group (n = 60). |
|---------------------------------------------|
| **Grade** | **Univariate** | **Multivariate** |
| | P | OR (95% C.I) | P | OR (95% C.I) |
| Age (years) | 0.072 | 0.90 (0.80–1.009) | | |
| Stage$^a$ (III) | 0.616 | 1.40 (0.11–16.45) | | |
| Affected lymph node | 0.328 | 0.950 (0.811–1.11) | | |
| Molecular type | | | | |
| Luminal | | | | |
| Triple negative | 0.023* | 0.067 (0.006–0.690) | 0.027* | 0.043*(0.003–0.702) |
| HER2 Positive | 0.134 | 5.0 (0.728–34.3) | 5.50 (0.59–51.2) | |
| Multicentric | 0.999 | – | – | |
| Carcinoma in situ | 0.999 | – | – | |
| ER | 0.023* | 15.0*(1.44–155.3) | 0.027* | 0.043*(0.003–0.702) |
| PR | 0.023* | 15.0*(1.44–155.3) | 0.027* | 0.043*(0.003–0.702) |
| HER2/neu | 0.850 | 1.20 (0.182–7.9) | 1.20 (0.182–7.9) | |
| Hb (g/dl) | 0.652 | 1.299 (0.59–2.82) | 1.299 (0.59–2.82) | |
| WBCs ($\times 10^3/\mu l$) | 0.004* | 0.492 (0.23–1.01) | 0.492 (0.23–1.01) | 0.061 | 0.394 (0.14–1.042) |
| Platelets ($\times 10^3/\mu l$) | 0.560 | 0.999 (0.977–1.02) | 0.999 (0.977–1.02) | |
| CA 15–3 (IU/ml) | 0.978 | 0.984 (0.9–1.13) | 0.984 (0.9–1.13) | |
| EMP2 (Normal) (>0.22) | 0.097 | 0.143 (0.014–1.41) | 0.143 (0.014–1.41) | |
| EMP2 (Malignant) (>5.84) | 1.000 | 1.00 (0.167–5.98) | 1.00 (0.167–5.98) | |
| β1-Integrin (Normal) (>0.70) | 0.998 | – | – | |
| β1-Integrin (Malignant) (>10) | 0.998 | – | – | |

$^a$: Reference (I + II), OR: Odd’s ratio, C.I: Confidence interval.

#: All variables with p < 0.05 was included in the multivariate.

*: Statistically significant at p ≤ 0.05.
Table 6
Univariate and multivariate analysis for the parameters affecting EMP2 expression in malignant tissue samples (n = 60).

| EMP2 malignant          | Univariate (P OR (95%C.I)) | Multivariate (P OR (95%C.I)) |
|-------------------------|----------------------------|------------------------------|
| Age (years)             | 0.152 (0.953–0.921–0.108)  | 0.146 (0.911–0.803–0.103)    |
| Affected lymph node     | 0.014* (0.103–0.017–0.628)  | 0.112 (0.014–1.156)          |
| Molecular type          | 0.715 (0.350–0.320–0.838)   | 0.639 (0.198–14.054)         |
| Luminal                 | 0.014* (0.103–0.017–0.628)  | 0.112 (0.014–1.156)          |
| Triple negative         | 0.014* (0.103–0.017–0.628)  | 0.112 (0.014–1.156)          |
| Her2 Positive           | 0.014* (0.103–0.017–0.628)  | 0.112 (0.014–1.156)          |
| Multicentric            | 0.014* (0.103–0.017–0.628)  | 0.112 (0.014–1.156)          |
| Carcinoma in situ       | 0.014* (0.103–0.017–0.628)  | 0.112 (0.014–1.156)          |
| ER                      | 0.014* (0.103–0.017–0.628)  | 0.112 (0.014–1.156)          |
| PR                      | 0.014* (0.103–0.017–0.628)  | 0.112 (0.014–1.156)          |
| HER2/neu                | 0.705 (1.333–0.301–5.91)    | 0.715 (1.306–0.311–5.48)     |
| Hb (g/dl)               | 0.676 (0.878–0.477–1.617)   | 0.934 (0.864–1.009)          |
| WBCs (× 10³/μl)         | 0.985 (0.985–0.985–1.000)   | 0.766 (0.182–3.21)           |
| Platelets (× 10³/μl)    | 0.791 (1.002–0.985–1.002)   | 0.871 (1.052–1.18–1.46)      |
| CA 15–3 (IU/ml)         | 0.458 (0.841–0.841–1.08)    | 0.766 (0.182–3.21)           |
| EMP2 (Normal)           | 0.715 (0.766–0.182–3.21)    | 0.715 (0.766–0.182–3.21)     |
| (> 0.22)                |                           |                              |
| β1-Integrin             | 0.715 (1.306–0.311–5.48)    | 0.715 (1.306–0.311–5.48)     |
| (Normal)                |                            |                              |
| (> 0.22)                |                            |                              |
| β1-Integrin             | 0.033* (5.50–1.145–26.41)   | 0.639 (0.198–14.054)         |
| (Malignant)             |                            |                              |
| (> 10)                  |                            |                              |

S: Reference (1 + II), OR: Odd’s ratio, C.I: Confidence interval.
#: All variables with p < 0.1 was included in the multivariate.
*#: Statistically significant at p ≤ 0.05.

Table 7
Univariate and multivariate analysis for the parameters affecting β1-Integrin expression in malignant tissue samples (n = 60).

| β1-Integrin malignant | Univariate (P OR (95%C.I)) | Multivariate (P OR (95%C.I)) |
|-----------------------|----------------------------|------------------------------|
| Age (years)           | 0.040* (0.927–0.86–0.99)   | 0.084 (0.864–1.009)          |
| Affected lymph node   | 0.655 (1.025–0.91–1.14)     | 0.699 (0.911–0.91–1.14)      |
| Molecular type        | 0.999 –                     | 0.999 –                      |
| Luminal               | 0.999 –                     | 0.999 –                      |
| Triple negative       | 0.919 (1.08–0.24–4.79)      | 0.919 (1.08–0.24–4.79)       |
| HER2 Positive         | 0.283 (0.357–0.054–2.34)    | 0.283 (0.357–0.054–2.34)     |
| Metacentric           | 0.368 (3.0–0.27–32.7)       | 0.368 (3.0–0.27–32.7)        |
| Carcinoma in situ     | 0.999 –                     | 0.999 –                      |
| ER                    | 0.999 –                     | 0.999 –                      |
| PR                    | 0.999 –                     | 0.999 –                      |
| HER2/neu              | 0.919 (1.08–0.24–4.79)      | 0.919 (1.08–0.24–4.79)       |
| Hb (g/dl)             | 0.652 (0.658–0.346–1.25)    | 0.652 (0.658–0.346–1.25)     |
| WBCs (× 10³/μl)       | 0.806 (1.054–0.69–1.60)     | 0.806 (1.054–0.69–1.60)      |
| Platelets (× 10³/μl)  | 0.647 (1.006–0.988–1.02)    | 0.647 (1.006–0.988–1.02)     |
| CA 15–3 (IU/ml)       | 0.221 (1.09–0.948–1.25)     | 0.221 (1.09–0.948–1.25)      |
| EMP2                  | 0.466 (0.583–0.137–2.48)    | 0.466 (0.583–0.137–2.48)     |
| (Normal)              | 0.023* (5.50–1.145–26.41)   | 0.076 (4.522–8.52–23.98)     |
| β1-Integrin (Benign)  | 0.466 (0.58–0.13–2.48)      | 0.466 (0.58–0.13–2.48)       |
| (> 5.84)              |                            |                              |
| (> 0.70)              |                            |                              |

S: Reference (1 + II), OR: Odd’s ratio, C.I: Confidence interval.
#: All variables with p < 0.05 was included in the multivariate.
#: Statistically significant at p ≤ 0.05.

4. Discussion

Breast cancer is characterized by molecular and histological heterogeneity. Although the diagnostic and prognostic factors related to breast cancer outcomes are being increasingly refined, there remains a need to improve on the specificity and sensitivity of prognostic markers which may impact the quality of life for breast cancer patients [21].

In the current study, there was a significant statistical difference between the two cancerous and normal studied groups as regards to the Hb level, HCT and MCHC, they were decreased in the cancer patients. While a non-significant difference existed as regards to RBC, MCV, MCH, WBC and platelets count.

This was in agreement with results reported by previous other studies of Leonard et al. Chaumard et al. and Macciò et al. [22–24].

A variety of factors are known to be involved in anemia development, and these relate directly to the tumor itself (blood loss, bone marrow infiltration or nutritional deficiencies) or to anticancer treatment [22].

In the current study, there was a significant statistical difference between the two studied groups as regards to the CA15-3 as it was elevated in cancer breast patients.

This result was in agreement with Muthuswamy and Raste, (2000) and Hashim et al. (2014) who reported an increased level of CA15-3 in breast cancer patients when compared to both women with benign tumor and healthy controls [25,26]. In addition, Gautam et al. (2015) found that there was a significant difference between benign and malignant breast lesions patients regarding serum CA 15-3 level, while there was a non-significant difference between benign breast lesions patients and controls [27]. Similarly, Aloabidi et al. (2015) reported that serum mean values of CA 15–3 were significantly higher in women with breast cancer than in controls [28].
On the other side, the studies of Duffy et al., Kucera et al. and Daniele et al. [29–31] found that CA15-3 lacked sensitivity for in situ or low stage invasive disease and lacked specificity for breast cancer preclude its use for detecting early breast cancer. Indeed, in patients with early or localized breast cancer, serum CA15-3 levels largely overlap those found in healthy women or those with benign breast disease.

In the present study, there was a significant increase in both EMP2 gene and β1-Integrin gene expression in malignant tissues as compared with healthy tissues. EMP2 is a 167-amino acid multi-pass membrane protein that contains four-transmembrane domains. EMP2 is a cancer-promoting protein, which is highly expressed in the malignancies derived from the epithelium and associated with tumorigenesis, in which triple-negative breast cancer (TNBC) is highly prominent. Obermayr et al. (2010) identified an EMP2 gene that can be used as one of the potential markers for the detection of circulating tumor cells (CTC) in the peripheral blood of patients with breast cancer [32]. Fu et al. (2014) discovered that EMP2 is a novel target in human breast cancer, and it was upregulated in 63% of invasive breast cancer and in 73% of TNBC tested. Similar to another study was found that EMP2 was highly expressed in over 70% of serous and endometrioid ovarian tumors compared to non-malignant ovarian epithelium using a human ovarian cancer tissue microarray [33]. Also Chen et al. (2019) reported that EMP2 is a potentially novel biomarker that can be used for capturing breast cancer cells and CTC in patient blood samples [34].

In the present study, there was a significant positive relation between the molecular type and each of EMP2 expression in malignant tissues and β1-Integrin expression in malignant tissue samples and a non-significant positive relation between the molecular type and each of EMP2 and β1-Integrin expression in healthy tissue samples. Goodglick et al. (2012) EMP2 expression that is highly expressed in the majority of breast cancer tumors examined compared to the healthy mammary epithelium. In particular, high levels of EMP2 have been observed in over 70% of TNBC cases examined [35].

Fu et al. (2014) examined the expression levels of EMP2 in breast cancer and found that it was expressed in 63% of invasive ductal carcinomas tested with low to minimal expression in normal mammary glandular and ductal cells. Of significance, greater than 70% of TNBC cases from two independent cohorts of patients expressed EMP2. Importantly, our results are concordant with several studies showing that EMP2 mRNA is upregulated in breast cancer and that its expression correlates with advanced and metastatic disease. Thus, its expression profile and localization on the plasma membrane make EMP2 an attractive target for passive immunotherapy with recombinant monoclonal antibodies [33].

β1-Integrin is a potential candidate biomarker of TNBC patients [36]. Reported that high β1-Integrin expression had a significant high metastatic stage, significant-high tumor recurrent rate, and significant low survival rate, compared to patients with low β1-Integrin expression. In addition, the average disease-specific survival time in patients with high β1-Integrin expression was significantly lower than that in patients with low β1-Integrin expression [37].

In the current study, univariate analysis of the studied parameters the β1-Integrin expression in malignant tissue samples of breast cancer was significantly increased with positive age and EMP2 expression in malignant tissue samples, and the β1-Integrin expression in malignant tissue samples of breast cancer was non significantly increased with positive age and EMP2 expression in malignant tissue samples of breast cancer. Integrin expression modulates cell invasion and migration properties, which can enhance tumor aggression and growth [38,39]. Studies have found that integrins are partially controlled by members of the tetratspan family [40]. Given that EMP2’s amino acid sequence is 33–43% similar to that of the tetratspanins, it is possible that EMP2 may also influence integrin expression [41]. Wedehra et al. (2002) found that EMP2 and β1-Integrins expression are simultaneously expressed in 60% of NIH3T3 fibroblast cells; thus, one well-supported hypothesis proposes that EMP2 regulates cell migration and invasion through β1-Integrins [42]. The influence of EMP2 on integrins has been validated in several studies including those by Morales et al. (2009) which showed a similar influence of EMP2 within ARPE-19 cells, a retinal pigmented epithelial cell line, and in studies by Lesko et al. (2017) in Madin-Darby Canine Kidney cells, a canine kidney epithelial cell line [43,44]. The presence of β1-Integrin residing on the cell surface has been observed to lead to changes in the surrounding ECM that further promotes tumor progression [42].

5. Conclusion

The gene expression of EMP2 and β1-Integrin are important markers for the severity of breast cancer and they are good indicators of its prognosis. When the gene expression of the EMP2 elevated in breast cancer tissue it is usually accompanied with an increase in β1-Integrin and CA 15-3.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbrep.2019.100708.

References

[1] W. Wu, E.K. Wagner, Y. Xiao, X. Rao, H. Dai, J. Han, J. Chen, A.M.V. Storniolo, Y. Liu, C. He, Tissue-specific co-expression of long non-coding and coding RNAs associated with breast cancer, Sci. Rep. 6 (2016) 32731.
[2] M. Kakarala, M.S. Wicha, Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy, J. Clin. Oncol. 26 (2008) 2813–2820.
[3] H. Kalrai, R.B. Clarke, Human breast epithelial stem cells and their regulation, J. Pathol. 208 (2006) 7–16.
[4] M. Fu, E.L. Marsh, R.A. Soloway, M. Alavi, V. Mah, Q. Zhou, A. Iasonos, L. Goodglick, L.K. Gordon, J. Braun, M. Wadehra, Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer, Clin. Cancer Res. 16 (2010) 3954–3963.
[5] L.K. Chung, P.E. Peliargus, A.M. Chan, J.V. Demos, C. Lagman, J.P. Sheppard, T. Nguyen, Y.L. Chang, S.A. Hojat, R.M. Prinz, L.M. Lais, et al., Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas, Brain Tumor Pathol. 35 (2018) 1–9.
[6] M. Kandouz, G. Batist, Gap junctions and connexins as therapeutic targets in cancer, Expert Opin. Ther. Targets 14 (2010) 681–692.
[7] M.Z. Gilcrease, Intergal signaling in epithelial cells, Cancer Lett. 247 (2007) 1–25.
[8] M. Esposito, Y. Kang, Targeting tumor-stromal interactions in bone metastasis, Pharmacol. Ther. 141 (2014) 222–233.
[9] D. Naci, K. Vuori, F. Aoudjit, Alpha2beta1 integrin in cancer development and chemoresistance, Semin. Cancer Biol. 35 (2015) 145–153.
[10] T.M. Scales, M. Parsons, Spatial and temporal regulation of integrin signaling during cell migration, Curr. Opin. Cell Biol. 5 (2011) 562–568.
[11] P.B. Dos Santos, J.S. Zanetti, A. Ribeiro-Silva, E.I. Beltrão, Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study, Diagn. Pathol. 7 (2012) 104.
[12] E. Hedrick, S.O. Lee, R. Doddapaneni, M. Singh, S. Safe, NR4A1 antagonists inhibit β1-integrin-dependent breast cancer cell migration, Mol. Cell. Biol. 36 (2016) 1383–1394.
[13] M.J. Duffy, Serum tumor markers in breast cancer: are they of clinical value? Clin. Chem. 52 (2006) 345–351.
[14] D.G. Telander, K.Y. Alfred, K.I. Forward, S.A. Morales, L.S. Morse, S.S. Park, L.K. Gordon, Epithelial membrane protein-2 in human proliferative vireotretinoinopathy and epiretinal membranes, Invest. Ophthalmol. Vis. Sci. 57 (2016) 3112–3117.
[15] J. Huafeng, Z. Deqing, D. Yong, Z. Yulian, H. Ailing, A cross-talk between integrin β4 and epidermal growth factor receptor induces gefitinib chemoresistance to gastric cancer, Cancer Cell Int. 18 (2018) 50.
[16] C.W. Elston, I.O. Ellis, Pathological prognostic factors in breast cancer. I. The value
of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology 19 (1993) 403–410.

[17] S.B. Edge, C.C. Compton, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Ann. Surg. Oncol. 17 (2010) 1471–1474.

[18] M.E.H. Hammond, D.F. Hayes, M. Dowsett, D.C. Allred, K.L. Hagerty, S. Badve, P.L. Fitzgibbons, G. Francis, N.S. Goldstein, M. Hayes, D.G. Hicks, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, Arch. Pathol. Lab Med. 134 (2010) e48–e72.

[19] A.C. Wolff, M.E. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Allred, R.J. Cote, M. Dowsett, P.L. Fitzgibbons, W.M. Hanna, A. Langer, L.M. McShane, S. Paik, M.D. Pegram, E.A. Perez, M.F. Press, A. Rhodes, C. Sturgeon, S.E. Taube, R. Tubbs, G.H. Vance, M. van de Vijver, T.M. Wheeler, D.F. Hayes, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Clin. Oncol. 25 (2007) 118–145.

[20] A. Goldhirsch, W.C. Wood, A.S. Coates, R.D. Gelber, B. Thürlimann, H.J. Senn, Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer, Ann. Oncol. 22 (2011) 1736–1747.

[21] P. Krishnan, S. Ghosh, B. Wang, M. Heyns, K. Graham, J.R. Mackey, O. Kovalchuk, S. Damaraaju, Profiling of small nuclear RNAs by next generation sequencing: potential new players for breast cancer prognosis, PLoS One 11 (2016) e0162622.

[22] R.C. Leonard, M. Untch, F. Von Koch, Management of anemia in patients with breast cancer: role of epoetin, Ann. Oncol. 16 (2005) 817–824.

[23] N. Chaumard, S. Limat, C. Villanueva, V. Nerich, P. Fagnoni, F. Bazan, L. Chaigneau, E. Dobi, L. Cals, X. Pivot, Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy, Breast 21 (2012) 464–467.

[24] A. Macioł, C. Madejda, G. Gramignano, C. Mulas, L. Tanca, M.C. Cherchi, C. Florio, I. Omoto, A. Barracca, T. Ganz, The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large prospective observational study, Haematologica 100 (2015) 124–132.

[25] S. Muthuswamy, A.S. Raste, Clinical significance of cancer antigen, CA 15.3 in breast cancer patients, BMC Canc. 10 (2010) 666–678.

[26] H.L. Yin, C.C. Wu, C.H. Ling, C.Y. Chai, M.F. Hou, S.J. Chang, H.P. Tsai, W.C. Hung, M.R. Pan, C.W. Luo, β1 integrin as a prognostic and predictive marker in triple-negative breast cancer, Int. J. Mol. Sci. 17 (2016) 1432.

[27] G.M. D’Abaco, A.J. Keyes, Integrins: molecular determinants of glioma invasion, J. Clin. Neurosci. 14 (2007) 1041–1048.

[28] M. Kanamori, T. Kawaguchi, M.S. Berger, R.O. Pieper, Intracranial microenvironment reveals independent opposing functions of host alphaVbeta3 expression on glioma growth and angiogenesis, J. Biol. Chem. 281 (2006) 37256–37264.

[29] D.G. Telander, S.A. Morales, S. Mareninov, R.O. Pieper, Epithelial membrane protein-2 interacts with beta1 integrins and regulates adhesion, J. Biol. Chem. 277 (2002) 41094–41100.

[30] I. Abbate, M. Quaranta, A. Mazzocca, Clinical usefulness of cancer antigen 15-3 in breast cancer patients before and after surgery, Open Breast Cancer J. 5 (2013) 1–6.

[31] A. Daniele, R. Divella, P. Trerotoli, M. Caringella, A. Paradiso, P. Casamassima, I. Abbate, M. Quaranta, A. Mazzocca, Clinical usefulness of cancer antigen 15-3 in breast cancer patients before and after surgery, Open Breast Cancer J. 5 (2013) 1–6.

[32] E. Obermayr, F. Sanchez-Cabo, M.K. Tea, C.F. Singer, M. Kraifer, M.B. Fischer, J. Sehouli, A. Reithaller, R. Horvat, G. Heine, D. Tung, Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female breast cancer patients, BMC Canc. 10 (2010) 666–678.

[33] M. Fu, E.L. Maresch, G.F. Helgauer, M. Kiyohara, Y. Qin, N. Ashiki, T.R. Daniels-Wells, N. Aziz, L.K. Gordon, J. Braun, Y. Elshihali, Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer, Mol. Cancer Ther. 13 (2014) 902–915.

[34] Q. Chen, L. Yao, D. Burner, B. Minev, L. Lu, M. Wang, W. Ma, Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer, Clin. Transl. Oncol. 21 (2019) 433–442.

[35] L. Goodglick, M. Fu, J. Braun, M. Wadehra, EMP2 regulates the tumor micro-environment and is a novel therapeutic target for triple negative breast cancer, Cancer Res. 72 (2012) 4621–4622.

[36] S. Klahan, W.C. Huang, C.H. Wang, W.C. Hung, M.S. Wu, Y.C. Lin, H.F. Lu, M.F. Hou, W.C. Chang, Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer, Pharmacol. Res. 104 (2016) 31–37.

[37] I.L. Yin, C.C. Wu, C.H. Ling, C.Y. Chai, M.F. Hou, S.J. Chang, H.P. Tsai, W.C. Hung, M.R. Pan, C.W. Luo, β1 integrin as a prognostic and predictive marker in triple-negative breast cancer, Int. J. Mol. Sci. 17 (2016) 1432.

[38] G.M. D’Abaco, A.J. Keyes, Integrins: molecular determinants of glioma invasion, J. Clin. Neurosci. 14 (2007) 1041–1048.

[39] M. Kanamori, T. Kawaguchi, M. S. Berger, R. O. Pieper, Intracranial microenvironment reveals independent opposing functions of host alphaVbeta3 expression on glioma growth and angiogenesis, J. Biol. Chem. 281 (2006) 37256–37264.